Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Interaction between complement receptor gC1qR and hepatitis C virus core protein inhibits T-lymphocyte proliferation
David J. Kittlesen, … , Thomas J. Braciale, Young S. Hahn
David J. Kittlesen, … , Thomas J. Braciale, Young S. Hahn
Published November 15, 2000
Citation Information: J Clin Invest. 2000;106(10):1239-1249. https://doi.org/10.1172/JCI10323.
View: Text | PDF
Article

Interaction between complement receptor gC1qR and hepatitis C virus core protein inhibits T-lymphocyte proliferation

  • Text
  • PDF
Abstract

Hepatitis C virus (HCV) is an important human pathogen that is remarkably efficient at establishing persistent infection. The HCV core protein is the first protein expressed during the early phase of HCV infection. Our previous work demonstrated that the HCV core protein suppresses host immune responses, including anti-viral cytotoxic T-lymphocyte responses in a murine model. To investigate the mechanism of HCV core-mediated immunosuppression, we searched for host proteins capable of associating with the core protein using a yeast two-hybrid system. Using the core protein as bait, we screened a human T cell–enriched expression library and identified a gene encoding the gC1q receptor (gC1qR). C1q is a ligand of gC1qR and is involved in the early host defense against infection. Like C1q, HCV core can inhibit T-cell proliferative responses in vitro. This core-induced anti–T-cell proliferation is reversed by addition of anti-gC1qR Ab in a T-cell proliferation assay. Furthermore, biochemical analysis of the interaction between core and gC1qR indicates that HCV core binds the region spanning amino acids 188 to 259 of gC1qR, a site distinct from the binding region of C1q. The inhibition of T-cell responsiveness by HCV core may have important implications for HCV persistence in humans.

Authors

David J. Kittlesen, Kimberly A. Chianese-Bullock, Zhi Qiang Yao, Thomas J. Braciale, Young S. Hahn

×

Figure 3

Options: View larger image (or click on image) Download as PowerPoint
Identification of core-binding region to the gC1qR. (a) Diagram for dele...
Identification of core-binding region to the gC1qR. (a) Diagram for deletion constructs. The COOH-terminal deletion constructs of HCV core protein (amino acids 1–152, 1–124, 26–124, 125–192) were generated by site-directed mutagenesis and inserted into the GST fusion vector pGEX4T.3. (b) GST-binding assay. The truncated forms of core protein as shown in the diagram were partially purified from bacteria transformed with the GST fusion plasmids. Purified GST fusion proteins expressing truncated forms of core protein were then examined for their binding ability to gC1qR, as described above. Lane 1: GST alone (29 kDa); lane 2: GST/core 125–192 (33.8 kDa); lane 3: GST/core 26–124 (37.7 kDa); lane 4: GST/core 1–124 (40.7 kDa); lane 5: GST/core 1–152 (43.4 kDa); lane 6: GST/core 1–192 (47.8 kDa). (c) Coomassie blue staining of the purified GST-core fusion proteins. Samples for each lane are same as in b.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts